HK1092791A1 - Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease - Google Patents

Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease

Info

Publication number
HK1092791A1
HK1092791A1 HK06110563.0A HK06110563A HK1092791A1 HK 1092791 A1 HK1092791 A1 HK 1092791A1 HK 06110563 A HK06110563 A HK 06110563A HK 1092791 A1 HK1092791 A1 HK 1092791A1
Authority
HK
Hong Kong
Prior art keywords
oxygenated
heterocycle containing
aspartyl protease
containing sulfonamide
sulfonamide inhibitors
Prior art date
Application number
HK06110563.0A
Other languages
English (en)
Inventor
Roger D Tung
Govinda Rao Bhisetti
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Priority claimed from HK02102257.2A external-priority patent/HK1042892B/zh
Publication of HK1092791A1 publication Critical patent/HK1092791A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/36—Alkylene carbonates; Substituted alkylene carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
HK06110563.0A 1995-04-19 1998-09-22 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease HK1092791A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/424,810 US5691372A (en) 1995-04-19 1995-04-19 Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
HK02102257.2A HK1042892B (zh) 1995-04-19 1998-09-22 含有天冬氨蛋白酶的磺胺抑制劑的氧化雜環

Publications (1)

Publication Number Publication Date
HK1092791A1 true HK1092791A1 (en) 2007-02-16

Family

ID=23683966

Family Applications (2)

Application Number Title Priority Date Filing Date
HK98110833A HK1009811A1 (en) 1995-04-19 1998-09-22 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
HK06110563.0A HK1092791A1 (en) 1995-04-19 1998-09-22 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK98110833A HK1009811A1 (en) 1995-04-19 1998-09-22 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease

Country Status (35)

Country Link
US (2) US5691372A (xx)
EP (3) EP1637528B1 (xx)
JP (1) JP4240532B2 (xx)
KR (1) KR100485237B1 (xx)
CN (1) CN1110491C (xx)
AP (2) AP9600827A0 (xx)
AR (1) AR004663A1 (xx)
AT (3) ATE479674T1 (xx)
AU (1) AU712913B2 (xx)
BG (1) BG102041A (xx)
BR (1) BR9608033A (xx)
CA (1) CA2217745C (xx)
CO (1) CO4700433A1 (xx)
CZ (1) CZ329497A3 (xx)
DE (3) DE69635679T2 (xx)
DK (1) DK0833826T3 (xx)
EA (1) EA000906B1 (xx)
EE (1) EE9700254A (xx)
ES (3) ES2171670T3 (xx)
GE (1) GEP20001915B (xx)
HK (2) HK1009811A1 (xx)
HU (1) HUP9801948A3 (xx)
IL (1) IL117962A0 (xx)
IS (1) IS4575A (xx)
MY (1) MY115797A (xx)
NO (1) NO974744D0 (xx)
NZ (1) NZ307342A (xx)
PE (1) PE43697A1 (xx)
PL (1) PL322904A1 (xx)
PT (1) PT833826E (xx)
SK (1) SK143097A3 (xx)
TR (1) TR199701194T1 (xx)
TW (1) TW404945B (xx)
WO (1) WO1996033187A1 (xx)
ZA (1) ZA962891B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
EP0656887B1 (en) 1992-08-25 1998-10-28 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5874449A (en) * 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
US6121273A (en) * 1996-12-31 2000-09-19 Gpi Nil Holdings, Inc N-linked sulfonamides of heterocyclic thioesters
CA2289654A1 (en) * 1997-05-17 1998-11-26 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
EA200000702A1 (ru) * 1997-12-24 2000-12-25 Вертекс Фармасьютикалз Инкорпорейтед Пролекарства ингибиторов аспартилпротеаз
NZ508855A (en) * 1998-06-19 2003-10-31 Vertex Pharma Sulfonamide inhibitors of HIV aspartyl protease
JP4776775B2 (ja) * 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
US6337340B1 (en) 1998-08-14 2002-01-08 Gpi Nil Holdings, Inc. Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6399648B1 (en) 1998-08-14 2002-06-04 Gpi Nil Holdings, Inc. N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
DE60024419T2 (de) * 1999-02-12 2006-08-17 Vertex Pharmaceuticals Inc., Cambridge Aspartyl-protease-inhibitoren
TNSN00027A1 (fr) * 1999-02-12 2005-11-10 Vertex Pharma Inhibiteurs de l'aspartyle protease
AR031520A1 (es) * 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
CZ300031B6 (cs) * 1999-10-06 2009-01-14 Tibotec Pharmaceuticals Ltd. Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5-ylsulfonyl) (isobutyl)amino]-1-benzyl-2-hydroxypropyl}karbamát a farmaceutický prípravek s jeho obsahem
IL151475A0 (en) 2000-03-30 2003-04-10 Bristol Myers Squibb Co Beadlets containing stavudine
AR035819A1 (es) * 2001-04-09 2004-07-14 Tibotec Pharm Ltd 2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos
WO2003057173A2 (en) * 2002-01-07 2003-07-17 Sequoia Pharmaceuticals Broad spectrum inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
AU2003300375A1 (en) * 2002-10-11 2004-05-04 Semplastics, L.L.C. Retaining ring for use on a carrier of a polishing apparatus
CA2507484A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2006104646A1 (en) * 2005-03-11 2006-10-05 Smithkline Beecham Corporation Hiv protease inhibitors
JP2007202679A (ja) * 2006-01-31 2007-08-16 Juki Corp ミシンの糸調子装置
JP2007202833A (ja) * 2006-02-02 2007-08-16 Juki Corp ミシンの糸調子装置
EP2491785A1 (en) * 2006-11-21 2012-08-29 Purdue Research Foundation Method and compositions for treating HIV infections
EP2244571A4 (en) 2008-01-17 2014-02-19 Purdue Research Foundation SMALL INHIBITORY MOLECULES OF HIV PROTEASES
US8791135B2 (en) 2008-07-01 2014-07-29 Purdue Research Foundation Nonpeptide HIV-1 protease inhibitors
WO2010006050A1 (en) 2008-07-09 2010-01-14 Purdue Research Foundation Hiv protease inhibitors and methods for using
CN105272991B (zh) * 2014-06-26 2017-11-07 成都中医药大学 一种化合物晶型
US11090030B2 (en) 2016-11-10 2021-08-17 Leltek Inc. Ultrasound apparatus and ultrasound emission method

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3743722A (en) * 1971-07-14 1973-07-03 Abbott Lab Anti-coagulant isolation
FR2459235A1 (fr) * 1979-06-14 1981-01-09 Sanofi Sa Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique
JPS5946252A (ja) * 1982-09-09 1984-03-15 Dainippon Ink & Chem Inc 含フツ素アミノカルボキシレ−トおよびその製法
JPS5948449A (ja) * 1982-09-13 1984-03-19 Dainippon Ink & Chem Inc 直鎖状含フツ素アニオン化合物およびその製造方法
JPS6171830A (ja) * 1984-09-17 1986-04-12 Dainippon Ink & Chem Inc 界面活性剤組成物
US4616088A (en) * 1984-10-29 1986-10-07 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitor
US4629724A (en) * 1984-12-03 1986-12-16 E. R. Squibb & Sons, Inc. Amino acid ester and amide renin inhibitors
DE3635907A1 (de) * 1986-10-22 1988-04-28 Merck Patent Gmbh Hydroxy-aminosaeurederivate
CH676988A5 (xx) * 1987-01-21 1991-03-28 Sandoz Ag
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91780A (en) * 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
WO1990007330A1 (en) * 1989-01-06 1990-07-12 The Regents Of The University Of California Selection method for specific useful pharmaceutical compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
EP0665215A1 (en) * 1990-06-01 1995-08-02 The Du Pont Merck Pharmaceutical Company 1,4-Diamino-2,3-dihydroxybutanes
TW225540B (xx) * 1990-06-28 1994-06-21 Shionogi & Co
WO1992008699A1 (en) * 1990-11-19 1992-05-29 Monsanto Company Retroviral protease inhibitors
EP0731088B1 (en) * 1990-11-19 2000-10-04 Monsanto Company Retroviral protease inhibitors
DK0813867T3 (da) * 1990-11-19 2005-10-03 Monsanto Co Retrovirale proteaseinhibitorer
DE69126987T2 (de) * 1990-11-19 1998-03-05 Monsanto Co Retrovirale protease-inhibitoren
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
EP0541168B1 (en) * 1991-11-08 1998-03-11 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
AU676479B2 (en) * 1992-05-20 1997-03-13 G.D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
WO1993023379A1 (en) * 1992-05-21 1993-11-25 Monsanto Company Retroviral protease inhibitors
AU669223B2 (en) * 1992-08-25 1996-05-30 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
EP0656887B1 (en) * 1992-08-25 1998-10-28 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
KR100296461B1 (ko) * 1992-08-25 2001-11-14 죤 에이치. 뷰센 레트로바이러스프로테아제저해제로서유용한n-(알카노일아미노-2-히드록시프로필)-술폰아미드
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
EP0885881B1 (en) * 1992-10-30 2003-03-12 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
PT810208E (pt) * 1992-10-30 2002-06-28 Searle & Co Derivados do acido hidroxietilamino-sulfamico n-substituido uteis como inibidores de proteases retrovrais
AU6135294A (en) * 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
TW281669B (xx) * 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
EP0715618B1 (en) * 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій

Also Published As

Publication number Publication date
DE69635679T2 (de) 2006-08-31
SK143097A3 (en) 1998-03-04
NZ307342A (en) 1999-04-29
BG102041A (en) 1998-09-30
PE43697A1 (es) 1997-10-11
HK1009811A1 (en) 1999-06-11
AP9600827A0 (en) 1997-10-17
EA000906B1 (ru) 2000-06-26
HUP9801948A3 (en) 2002-04-29
AR004663A1 (es) 1999-03-10
EP1637528B1 (en) 2010-09-01
ATE212344T1 (de) 2002-02-15
EP1136479B1 (en) 2005-12-28
PL322904A1 (en) 1998-03-02
US5990155A (en) 1999-11-23
AP9701104A0 (en) 1997-10-31
JPH11504628A (ja) 1999-04-27
GEP20001915B (en) 2000-01-05
KR100485237B1 (ko) 2005-09-30
CA2217745A1 (en) 1996-10-24
TW404945B (en) 2000-09-11
EP0833826A1 (en) 1998-04-08
AP862A (en) 2000-08-04
CN1184474A (zh) 1998-06-10
EP0833826B1 (en) 2002-01-23
WO1996033187A1 (en) 1996-10-24
EP1637528A1 (en) 2006-03-22
ATE314360T1 (de) 2006-01-15
CA2217745C (en) 2011-07-05
TR199701194T1 (xx) 1998-03-21
AU5665596A (en) 1996-11-07
PT833826E (pt) 2002-06-28
EA199700330A1 (ru) 1998-04-30
EE9700254A (et) 1998-04-15
BR9608033A (pt) 1999-01-12
DK0833826T3 (da) 2002-05-06
AU712913B2 (en) 1999-11-18
IL117962A0 (en) 1996-08-04
DE69635679D1 (de) 2006-02-02
HUP9801948A2 (hu) 1999-09-28
DE69618779D1 (de) 2002-03-14
CO4700433A1 (es) 1998-12-29
CN1110491C (zh) 2003-06-04
ES2256117T3 (es) 2006-07-16
DE69638252D1 (de) 2010-10-14
MY115797A (en) 2003-09-30
NO974744L (no) 1997-10-14
JP4240532B2 (ja) 2009-03-18
NO974744D0 (no) 1997-10-14
DE69618779T2 (de) 2002-08-29
EP1136479A1 (en) 2001-09-26
US5691372A (en) 1997-11-25
ZA962891B (en) 1996-10-15
IS4575A (is) 1997-10-02
ATE479674T1 (de) 2010-09-15
ES2171670T3 (es) 2002-09-16
ES2351970T3 (es) 2011-02-14
KR19990007823A (ko) 1999-01-25
CZ329497A3 (cs) 1998-03-18

Similar Documents

Publication Publication Date Title
HK1092791A1 (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
AP9701119A0 (en) THF-containing sulfonamide inhibitors of aspartyl protease
AP9300572A0 (en) Novel sulfonamide inhibitors of aspartyl protease
AP2000002023A0 (en) Sulfonamide inhibitors of aspartyl protease
ZA939285B (en) Inhibitors of aspartyl protease
PL323710A1 (en) Reversible inhibitors of cysteinic protease
HUP9902083A3 (en) Sulfonamide inhibitors of matrix metalloproteinases
AU2012199A (en) Prodrugs of aspartyl protease inhibitors
PL314838A1 (en) Inhibitors of bp-iv-serine protease
HUP0101598A3 (en) Prodrugs of aspartyl protease inhibitors and medicaments containing them
IL128378A0 (en) Inhibitors of cysteine protease
HUP0101831A3 (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors and medicaments containing them
EP0923535A4 (en) CYSTEINE PROTEASE INHIBITORS
PL328665A1 (en) Inhibitors of serinic protease
AP9700961A0 (en) Aspartyl protease inhibitors
GB2299583B (en) Peptidyl inhibitors of serine proteases
HK1042892A1 (en) Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease
SI0846110T1 (en) Thf-containing sulfonamide inhibitors of aspartyl protease
ZA938470B (en) Sulfonamide inhibitors of aspartyl protease
ZA969078B (en) Inhibitors of cysteine protease.
SI0874836T1 (en) Sulfonamide inhibitors of matrix metalloproteinases
GB9521813D0 (en) Peptide inhibitors of serine proteinases
GB9520761D0 (en) Protease inhibitors
SI0936912T1 (en) Inhibitors of cysteine protease

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20160417